ADMA Stock — ADMA Biologics Inc: Cash, EV, Pipeline

What they do

Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. Through our ADMA BioManufacturing business segment, we currently have three products with U.S.

Source: 10-K FY2025 via SEC EDGAR

Share price

$12.73

Market cap

$2,824.2M

Cash

$124.6M

Enterprise value

$2,895.5M

Balance sheet

Cash	$124.6M
Debt	$195.9M
Net cash	-$71.3M
Enterprise value	$2,895.5M
Basic shares	221.8M shares
Fully diluted shares	233.6M shares
Fully diluted market cap	$2,973.4M
Cash per share	$0.56
Quarterly burn	+$29.5M generated

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

224.0M

Pre-funded warrants

0.0M

Options

5.1M

RSUs

4.5M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

233.6M

Cap table as of 2026-06-30.

Price history

Loading ADMA daily closes…

Loading price history…

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

ASCENIV

Approved · Active Modality: plasma-derived IVIG (immunoglobulin)

Partnerships Biotest AG: exclusive license to market and sell ASCENIV in Europe and certain Northern Africa/Middle East countries (2012 agreement; in-kind services and cash milestones paid; adjustable royalty on territory revenues for 20 years from first commercial sale)

Indications

Primary Humoral Immunodeficiency (PI/PIDD) (Approved)

Status note FDA approved April 2019. Label expanded to pediatric patients ages 2+ in May 2026. Yield-enhancement PAS approved April 2025. Filing notes potential future evaluation in RSV-infected immune-compromised patients, not yet a stated trial.

BIVIGAM

Approved · Active Modality: plasma-derived IVIG (immunoglobulin)

Indications

Primary Humoral Immunodeficiency (PI/PIDD) (Approved)

Status note FDA approved May 2019 for PI in adults and pediatric patients 2+. Yield-enhancement PAS approved April 2025; FY2026 is first full year of yield-enhanced production.

Nabi-HB

Approved · Active Modality: plasma-derived hyperimmune globulin

Target hepatitis B surface antigen (HBsAg)

Indications

Acute exposure to blood containing HBsAg and other Hepatitis B exposures (Approved)

Status note Hepatitis B Immune Globulin (Human).

SG-001

Preclinical · Active Modality: plasma-derived hyperimmune globulin

Target S. pneumoniae

Indications

S. pneumoniae infection in vaccine-naive and immune-compromised patients (Preclinical)

Catalysts

— fiscal year 2026

Status note Pilot-scale batch produced 2024; animal studies ongoing. Commissioner National Priority Voucher (CNPV) application submitted September 2025, if accepted could accelerate FDA review by two fiscal quarters or more.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Stonepine Capital	740,000	no change	4.72%	2026-08-17
Perceptive Advisors	113,765	-353,468	0.01%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ADMA — ADMA Biologics Inc ☆

What they do

Balance sheet

Share structure

Price history

Upcoming catalysts

Pipeline assets

Specialist fund holders

Latest news

ADMA — ADMA Biologics Inc